Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble
Argenx stock tumbled Thursday after its drug, Vyvgart, beat sales expectations. But the beat wasn't strong enough for investors. The post Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble appeared first on Investor's Business Daily.
Argenx stock tumbled Thursday after its drug, Vyvgart, beat sales expectations. But the beat wasn't strong enough for investors.
The post Argenx Beats Sales Expectations — But Not By Enough — And Shares Tumble appeared first on Investor's Business Daily.
iShook Opinion
"iShook Opinion" by Beni E Rachmanov, CEO & Founder of iShook. Explore captivating perspectives on entertainment, lifestyle, and sports at ishookdaily.com. Your go-to for engaging insights.
